Gene Therapy Hub

"Cure" is a strong word. Some gene therapies — particularly ex vivo CRISPR approaches — aim for a one-time correction that could last years or decades. Others, like mRNA, require ongoing dosing. The goal in most programmes is to substantially reduce symptoms and disease burden, not necessarily achieve completely normal skin. For monogenic forms (single gene mutation) the potential for a functional cure is real, but it depends on delivery efficiency and how many cells are corrected.

Topical approaches (mRNA, some ASO) have a strong safety profile because they don't enter the bloodstream or target systemic tissues. Ex vivo CRISPR — where cells are edited outside the body and grafted back — avoids off-target systemic editing risks. Systemic AAV delivery carries more risk but is rarely used for skin conditions. Phase 1 data from ichthyosis programmes published so far has not shown serious adverse events, but trial sample sizes are small. As with any emerging therapy, long-term follow-up data is limited.

Trials prioritise severe cases first for ethical reasons — the benefit-to-risk ratio needs to clearly favour treatment. For milder presentations like Ichthyosis Vulgaris, the bar is higher and existing treatments (emollients, retinoids) are already reasonably effective. However, if a therapy achieves approval, it would typically be available for all severities over time. Biologic approaches like dupilumab have a better near-term profile for mild-moderate cases.

Genetic confirmation of your specific mutation is almost always required — a pathogenic variant in the relevant gene (e.g. ABCA12 for Harlequin, TGM1 for Lamellar). Age, disease severity, prior treatments, and comorbidities also factor in. The fastest route is: (1) get genetically tested via NHS clinical genetics, (2) register with ISG or FIRST patient registries, (3) ask your dermatologist to enquire with trial sites directly. Trial coordinators are generally very responsive to patient enquiries.

XLI has the most advanced disease-modifying programme of any ichthyosis type right now. Dermavant's topical STS enzyme replacement is in Phase 3, with readout expected Q3 2026. This is not gene therapy per se — it's enzyme replacement — but it targets the root cause (STS deficiency) rather than symptoms. If approved, it would be the first ever approved treatment specifically for XLI. Traditional gene therapy programmes for XLI are also in preclinical development.